4MOVING BIOTECH

Health Canada Authorizes 4Moving Biotech's Phase 2a Trial for Novel Knee Osteoarthritis Treatment

2 months ago

• Health Canada has approved 4Moving Biotech's INFLAM MOTION Phase 2a clinical trial for 4P004, a GLP-1 analog designed for intra-articular use in knee osteoarthritis patients. • The multicenter, randomized, double-blind study will enroll 129 patients across the EU, US, and Canada to evaluate 4P004's potential as the first disease-modifying osteoarthritis drug (DMOAD). • 4P004 targets multiple joint tissues with analgesic, anti-inflammatory, anti-catabolic, and anabolic properties, potentially slowing disease progression and improving joint function.